|
|
|
| Analysis on Efficacy and Safety of Conformal Intensity-modulated Radiotherapy combined with Targeted Therapy in the treatment of Brain Metastases from Lung Cancer |
| RAO Jian, ZHANG Qinhua, LIN Xiuxin, et al |
| Jiangmen Central Hospital, Guangdong Jiangmen 529030, China |
|
|
|
|
Abstract Objective: To explore the efficacy and safety of conformal intensity-modulated radiotherapy combined with targeted therapy in the treatment of brain metastases from lung cancer. Methods: 82 patients with brain metastases from lung cancer admitted to hospital from January 2012 to June 2017 were selected and divided into control group and observation group according to the random number table method, with 41 cases in each group. Control group was given conformal intensity-modulated radiotherapy combined with chemotherapy, and observation group was given conformal intensity-modulated radiotherapy combined with targeted therapy. The serum levels of tumor indexes factors were detected by ELISA. The serum levels of tumor indexes factors, efficacy, adverse reactions and 1-year survival rate were observed and compared between the two groups. Results: The total effective rate in observation group was significantly higher than that in control group (92.68% vs 70.73%) (χ2=6.609, P=0.010). The serum levels of TNF-α, NSE, SCC-Ag and CEA in observation group were significantly lower than those in control group (t=5.122, 13.013, 13.416, 22.857, P=0.000, 0.000, 0.000, 0.000). There was no significant difference in the incidence rate of adverse reactions between the two groups after treatment (P>0.05), and they were tolerated. The 1-year PFSand 1-year OS were 63.42% and 68.29% in observation group, which were significantly higher than those in control group with 36.56% and 46.34% (Log-rank χ2=6.874, 4.797, P=0.008, 0.029). Conclusions: Intensity modulated radiation therapy (IMRT) combined with targeted therapy can be used for symptomatic patients with brain metastases from lung cancer. The clinical efficacy is significantly better than that of radiotherapy and chemotherapy, and the side effects are tolerable.
|
|
|
|
|
|
[1] Mok T S,Wu Y L,Ahn M J,et al.Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.[J].N Engl Med,2017,376(7):629~640.
[2] 郭卫东.探析DC-CIK联合化疗治疗晚期非小细胞肺癌的临床效果[J].中华肿瘤防治杂志,2016,23(5):335~336.
[3] 张卉,张树才.非小细胞肺癌EGFR基因靶向治疗研究进展[J].中国肺癌杂志,2017,20(1):61~65.
[4] 徐咏梅,杨国旺,胡凤山,等.中药辅助动脉灌注化疗治疗晚期非小细胞肺癌53例临床疗效观察[J].中医杂志,2017,58(2):138~140.
[5] Schwartz L,Bogaerts J R,Shankar L,et al.Evaluation of lymph nodes with RECIST 1.1.[J].European Journal of Cancer,2009,45(2):261~267.
[6] 臧瑜,于虹,李妍,等.肺癌患者症状群的调查研究[J].中华护理杂志,2016,51(3):316~320.
[7] Bo L I,Sun S Z,Chen X L,et al.Characteristics and treatment of brain metastasis in non-small cell lung cancer patients with different epidermal growth factor receptor mutation status[J].Chinese Journal of Cancer Prevention&Treatment,2017,24(5):328~331.
[8] Yadav M,Singh A K,Kumar H,et al.Epidermal growth factor receptor inhibitor cancer drug gefitinib modulates cell growth and differentiation of acute myeloid leukemia cells via histamine receptors[J].Biochim Biophys Acta,2016,1860(10):2178~2190. |
|
|
|
2019, Vol. 25 
